Save
Fertility sparing surgery in cervical cancer patients outside controlled trials – a multicenter retrospective cohort trial (CEEGOG Cx-03; ENGOT-CX14)
ESGO eAcademy, Jiri Slama, 343768
STELLA-2 trial: Surgical complications comparing extraperitoneal vs transperitoneal MIS aortic staging in early stage ovarian and endometrial cancer
ESGO eAcademy, Vicente Bebia Conesa, 343766
Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment
ESGO eAcademy, Alicia Leon-Castillo, 343764
Molecular subclassification of vulvar squamous cell carcinoma: prognostic significance and reproducibility
ESGO eAcademy, Emily F. Thompson, 343760
Laser skinning vulvectomy
ESGO eAcademy, Michael Halaska, 341012
ONLINE ENYGO video session: Minor and plastic reconstructive procedures in vulvar malignant and premalignant lesions
ESGO eAcademy, Faculty / Presenters, 341009
Impact of COVID-19 on gynaecological cancer outcomes
ESGO eAcademy, Sudha Sundar, 341004
State of the art 14: Management of medical complications related to new therapies - Q&A
ESGO eAcademy, Faculty / Presenters, 340996
Management of PARPi, ADC and other targeted-therapy-related side effects
ESGO eAcademy, Banerjee Susana, 340995
Natural history of HPV infection with differing subtypes; an epidemiological perspective
ESGO eAcademy, Karin Sundström, 340988
Utilising the cervical microbiome and epigenome in order to predict women’s cancers risks
ESGO eAcademy, Martin Widschwendter, 340987
Best Oral session 3: Ovarian cancer - Q&A
ESGO eAcademy, Faculty / Presenters, 343758
Can pharmacogenetics predict chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy?
ESGO eAcademy, Katie Dorr, 343755
Analysis of patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer in the phase 3 ARIEL3 study
ESGO eAcademy, Jonathan Ledermann, 343754
Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT
ESGO eAcademy, Florian Heitz, 343753
HPV natural infection, its clearance and vaginal flora - Q&A
ESGO eAcademy, Faculty / Presenters, 343749
Management of check-point inhibitor-related side effects
ESGO eAcademy, Antonio Gonzalez-Martin, 340994
Cervical pre-invasive and invasive disease, HPV clearance and microbiota
ESGO eAcademy, Murat Gultekin, 340986
The impact of intensive follow-up on health-related quality of life and costs in endometrial cancer patients: data from the TOTEM trial NCT00916708
ESGO eAcademy, Paolo Zola, 346117
A randomised phase II study of combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. NSGO/ENGOT-EN1/FANDANGO
ESGO eAcademy, Faculty / Presenters, 346115
QPOLE: multiplex qPCR hotspot testing of pathogenic POLE mutations: a rapid, simple and reliable approach for POLE assessment in endometrial cancer
ESGO eAcademy, Anne-Sophie van den Heerik, 346113
Primary Imiquimod Treatment versus Surgery for Vulvar Intraepithelial Neoplasia - PITVIN study. A Randomized Clinical Trial
ESGO eAcademy, Gerda Trutnovsky, 346111
State of the art 12: Prevention strategies in high risk women - Q&A
ESGO eAcademy, Faculty / Presenters, 340968
Defining Notch signaling mechanisms associated with the cardiovascular phenotypes of Alagille Syndrome
ESGO eAcademy, Shelby Thomas, 343914
Role of early salpingectomy and delayed oophorectomy in high-risk women
ESGO eAcademy, Joanne A. De Hullu, 340967
Should we screen for ovarian cancer in high-risk women - current status and future strategies
ESGO eAcademy, Usha Menon, 340966
Population-based genetic testing for cancer prevention
ESGO eAcademy, Ranjit Manchanda, 340965
Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)
ESGO eAcademy, Floriane Jochum, 343747
ERAS protocols in gynaecological oncology. Should we include thoracic epidural analgesia?
ESGO eAcademy, Anastasios Pandraklakis, 343745
ESGO, ISSVD, EFC and ECSVD Consensus statement: Pre-invasive vulvar and vaginal lesions
ESGO eAcademy, Murat Gultekin, 343723
Management of VIN
ESGO eAcademy, Mario Preti, 343724
Management of VaIN
ESGO eAcademy, Vesna I. Kesic, 343725
Reconstructive surgery in the surgical management of VIN and VaIN
ESGO eAcademy, Pawel Knapp, 343726
Novel non-surgical prevention strategies in high-risk women
ESGO eAcademy, Susan Domchek, 340964
Preinvasive disease of vulva and vagina - Q&A
ESGO eAcademy, Faculty / Presenters, 343727
European enhanced recovery after surgery (ERAS) gynecological oncology survey: Current state of perioperative practice
ESGO eAcademy, Natalia R. Gómez-Hidalgo, 343743
Short- and long-term urological complications after surgery for early-stage cervical cancer
ESGO eAcademy, María Tiermes Marina Martín, 343741
Advanced gynecological cancer: Quality of life one year after diagnosis
ESGO eAcademy, Björg Jónsdóttir, 343739
Loss of ovarian function in young patients with cancer: prognostic model
ESGO eAcademy, Raffaella Cioffi, 343737
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective study
ESGO eAcademy, Hanna Valstad, 343735
Evolution of terminology and classification of VIN
ESGO eAcademy, Jacob Bornstein, 342915
Tumor cell dissemination is independent from endometrial carcinoma molecular subtypes
ESGO eAcademy, Lea Volmer, 343733
Indocyanine green to assess vascularity of ileal conduit anastomosis during pelvic exenteration for recurrent/persistent gynecological cancer
ESGO eAcademy, Bizzarri Nicolo, 343731
Palbociclib and metformin show anticancer efficacy in high grade serous ovarian cancer
ESGO eAcademy, Irina Tsibulak, 343729
Gestational Trophoblastic Disease – The need to collaborate beyond country borders - Q&A
ESGO eAcademy, Faculty / Presenters, 340953
Scientific session 14: Regional challenges in gynaecological cancer and access to care - Q&A
ESGO eAcademy, Nadeem R. Abu-Rustum, 340960
Establishing a new GTD centre: a Serbian experience
ESGO eAcademy, Vesna I. Kesic, 340952
Personalised treatment in gynaecological sarcoma
ESGO eAcademy, Isabelle Ray-Coquard, 340945
Challenges in gynaecological cancer care and access in developing nations
ESGO eAcademy, Jalid Sehouli, 340959
Hot news in GTD management through international collaboration
ESGO eAcademy, Michael Seckl, 340951
Rare variants of ovarian cancer
ESGO eAcademy, Elena Ioana Braicu, 340944
Rare gynaecological tumours: How developments in pathobiology help treatment and research - Q&A
ESGO eAcademy, Faculty / Presenters, 343722
Elimination of Cervical Cancer European Experience
ESGO eAcademy, Artem Stepanyan, 340958
International networks for rare tumours, what the EOTTD can contribute to care and education
ESGO eAcademy, Christianne Lok, 340950
Rare variants of endometrial carcinoma
ESGO eAcademy, Xavier Matias-Guiu, 340943
Scientific session 13: Rare gynaecological tumours: How developments in pathobiology help treatment and research
ESGO eAcademy, Faculty / Presenters, 340939
State of the art 11: Does the tumour microenvironment hold the key to the success of immunotherapy? - Q&A
ESGO eAcademy, Faculty / Presenters, 340932
Updates on combinatorial approaches in ovarian cancer immunotherapy
ESGO eAcademy, Christian Marth, 340931
Immunological configuration of ovarian carcinoma: Impact on disease outcome and response to immunotherapy
ESGO eAcademy, Jitka Palich Fucikova, 343708
Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer – A National Prospective Multicentre Study (SENTIREC Trial)
ESGO eAcademy, Sara Sponholtz, 343712
Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service
ESGO eAcademy, Cheryl Yim, 343714
The impact of micrometastases in cervical cancer patients - a retrospective study of the SCCAN (Surveillance in Cervical CANcer) project
ESGO eAcademy, Lukas Dostalek, 343716
SENTIX -  Accuracy of preoperative local staging in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
ESGO eAcademy, Jaroslav Klat, 343718
Resection of the upper paracervical lymphovascular tissue should be a part of a pelvic sentinel lymph node algorithm in early stage cervical cancer
ESGO eAcademy, Oscar Lührs, 343720
Debate 3: Management of patients with "intermediate risk" cervical cancer
ESGO eAcademy, Faculty / Presenters, 340935
Debate 3: Management of patients with "intermediate risk" cervical cancer
ESGO eAcademy, Alexandra Taylor, 340938
Prevention of burn-out for health care providers
ESGO eAcademy, Vesna I. Kesic, 340925
State of the art 9: Are we reaching the safety limit for fertility preservation in gynaecologic malignancies? - Q&A
ESGO eAcademy, Faculty / Presenters, 340914
Cancer is a “WE-disease” – family and partner involvement as the main caregivers
ESGO eAcademy, Annette Hasenburg, 340924
Could we preserve fertility with any myometrial infiltration in endometrial cancer?
ESGO eAcademy, Alexandros Rodolakis, 340913
Scientific session 12: Empowering life - Q&A
ESGO eAcademy, Faculty / Presenters, 343707
Cervical cancer: Image-guided external beam radiotherapy and brachytherapy
ESGO eAcademy, Remi Nout, 343703
Empowering life for patients
ESGO eAcademy, Joachim Weis, 340923
Image-guided radiotherapy for primary vaginal cancer: Impact on disease outcome and morbidity
ESGO eAcademy, Lars Fokdal, 343704
Endometrial cancer. Don´t forget curative, brachytherapy-based radiotherapy when surgery is contraindicated
ESGO eAcademy, Elzbieta van der Steen-Banasik, 343705
Brachytherapy in gynaecological tumours (cervical, endometrial, vaginal) Q&A
ESGO eAcademy, Faculty / Presenters, 343706
Fertility preservation in ovarian cancer: safety boundaries
ESGO eAcademy, Ignacio Zapardiel, 340912
Should neoadjuvant chemotherapy be a standard in fertility sparing treatment of cervical cancer?
ESGO eAcademy, Michael Halaska, 340911
Scientific session 11: Selection of patients with relapsed ovarian cancer for surgery - Q&A
ESGO eAcademy, Faculty / Presenters, 340888
Tumour board 3: Borderline ovarian tumours: Individualising patient management - Discussion
ESGO eAcademy, Faculty / Presenters, 340906
Surgery in recurrent ovarian cancer - Improving selection process by integrating molecular biology
ESGO eAcademy, Nicole Concin, 340887
Serous borderline tumour/ low-grade serous carcinoma: oncological treatments (what and when)
ESGO eAcademy, Charlie Gourley, 340905
Surgery in recurrent ovarian cancer - Improving selection process by integrating pre-operative imaging & laparoscopy into the clinical algorithm
ESGO eAcademy, Fagotti Anna, 340886
Abdominal wall complications after GynOnc surgery - treatment and management
ESGO eAcademy, Luis Chiva, 340896
Serous borderline tumours: does implant type matter and limits of fertility-preserving surgery
ESGO eAcademy, Philippe Morice, 340904
Miscellaneous complications in GynOnc surgery - interactive workshop with case reports: diagnosis, treatment and management
ESGO eAcademy, Beyhan Ataseven, 340895
Pathology of borderline ovarian tumours: more than one disease
ESGO eAcademy, Glenn McCluggage, 340903
What is the State-of-the-Art: RCTs in surgery for recurrent Ovarian Cancer
ESGO eAcademy, Andreas du Bois, 340885
Video abstract 3 - Laterally extended pelvic resection with complete resection of ureter and nephrectomy
ESGO eAcademy, Michal Zikan, 340880
Video abstract 2 - ID 848: Indocyanine green to assess vascularity of Bricker ileal conduit anastomosis during pelvic exenteration for recurrent cervical cancer
ESGO eAcademy, Bizzarri Nicolo, 340879
Video abstract 1 - ID 1021: V-Y flap reconstruction for vulvar cancer recurrence after primary radiotherapy
ESGO eAcademy, Sergi Fernandez, 340878
Pelvic exenteration-Out of the box
ESGO eAcademy, Gwenael Ferron, 340877
Pelvic reconstruction
ESGO eAcademy, Cagatay Taskiran, 340876
Best oral - late breaking abstracts 2 - Q&A
ESGO eAcademy, Faculty / Presenters, 343702
Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative.
ESGO eAcademy, Stefan Kommoss, 343698

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings